QLS-7305

N/A

Report date: 2026/05/13 20:02:10
NME

Base Information

Drug NameQLS-7305
Drug Alias NameQLS7305QLS-7305
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Small Interfering RNA
Mechanisms of ActionComplement system proteins modulators
TargetsComplement system proteins
Therapy Area/IndicationsC3 glomerulopathyHemoglobinuria, ParoxysmalNephrosis +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesQilu Pharmaceutical Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesQilu Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsC3 glomerulopathyHemoglobinuria, ParoxysmalNephrosis +[5] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A